Myriad Genetics, Inc. (MYGN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
$6.29+4.49%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-05
QuarterlyIQ Insights · MYGN
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC).
Stated in 2 of 3 supplied quarters. Management reported: “Average revenue per CCC test in the third quarter 2026 was higher than in the second quarter 2026 and reflects our team's ongoing work and early progress with payer engagement and revenue cycle management initiatives," said Sam Raha, President and CEO, Myriad Genetics.” “|| Cancer Care Continuum and Mental Health Revenue | $620 - $630 | With the announced sale of Prenatal Health on October 20, 2026, a break out of Prenatal Health revenue for full-year 2026 revenue guidance is provided.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC).”
“"We are seeing strong performance across a number of key areas, including the Cancer Care Continuum as we begin to realize a return on our focused strategy.”
“This announcement is the direct outcome of our disciplined strategic review process, which is focused on sharpening our portfolio, enhancing operational execution, and driving shareholder value,” sa…
Adjusted operating expenses in the third quarter of 2026 increased $9.9 million year-over-year to $149.9 million, reflecting the company's multi-year investment in key strategic areas.
Stated in 2 of 3 supplied quarters. Management reported: “We have activated an initiative called Ascend to increase organizational efficiency, effectivity and scalability and are being supported by a leading professional services firm.” “Adjusted operating expenses in the third quarter of 2026 increased $9.9 million year-over-year to $149.9 million, reflecting the company's multi-year investment in key strategic areas.”
“Adjusted operating expenses in the third quarter of 2026 increased $9.9 million year-over-year to $149.9 million, reflecting the company's multi-year investment in key strategic areas.”
“We have activated an initiative called Ascend to increase organizational efficiency, effectivity and scalability and are being supported by a leading professional services firm.”
Management is reviewing the product portfolio and directing strategic focus and investment toward its Cancer Care Continuum business.
Management is engaging payers and executing revenue-cycle initiatives to improve reimbursement predictability and mitigate average revenue per test pressure, particularly in hereditary cancer testing.
Over the trailing year it converted 0.70x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.